Gasparini PVF, Matias AM, Torezani-Sales S et al (2021) High-fat and combined high-fat and sucrose diets promote cardiac oxidative stress independent of Nox2 redox regulation and obesity in rats
Safety Considerations and Provider Oversight During the Timeline Early side effectsnausea, constipation, vomitingoccur in 2040% of users and typically resolve within 12 weeks
High-dose GHRP-6: Moderate-high risk Why it's concerning: Significant appetite increase (can derail diet) Prolactin elevation (gynecomastia risk in sensitive individuals) Cortisol increase at high doses Water retention When it might be acceptable: Moderate doses (100-200mcg, not 300+mcg) Short-term use (8-12 weeks) If appetite increase isn't problematic Safer alternatives: Ipamorelin (no prolactin/cortisol increase) Lower GHRP-6 doses with careful monitoring Hexarelin: Higher risk than benefits justify Why it's problematic: Rapid desensitization (must cycle frequently) Cortisol and prolactin elevation Heart stress concerns Diminishing returns Limited use cases: Very short cycles (4 weeks maximum) Experienced users only With careful monitoring Better options: Ipamorelin for sustained results GHRP-2 for middle ground Synthetic growth hormone: Highest overall risk Why avoid: Complete shutdown of natural GH production Organ growth (hands, feet, jaw, internal organs) Insulin resistance Expensive Requires PCT (post-cycle therapy) Legal issues in most countries Only justified for: Medical growth hormone deficiency Under physician supervision Replacement doses, not supraphysiological Much safer alternatives: CJC-1295 + Ipamorelin stack Natural peptides that stimulate endogenous GH No shutdown, no PCT needed See peptides vs steroids and peptides vs SARMs for safety comparisons
Brain fog, paradoxically, can result from over-activation of excitatory pathways without corresponding GABAergic balance
According to forecasts, the market for anti-obesity medications could be worth between 64bn and 120bn a year by 2030
